Lake Street downgraded Optinose (OPTN) to Hold from Buy with a price target of $9, down from $17, after Paratek Pharmaceuticals announced it will be acquiring OptiNose for up to $330M, or $14 per share. Shareholders will be granted contingent value rights worth up to $5 per share, notes the analyst, who expects no additional bids and for the deal to close in mid-2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPTN: